Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Forst

Showing results (41-50 of 96) with videos related to

Pageof 10
Sort By:
Clinical Laboratory|April 13, 2004
Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotypingA Weise, S Grundler, D Zaumsegel, et al.
Diabetes, Obesity & Metabolism|February 2, 2013
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metforminC Kapitza, T Forst, H-V Coester, et al.
Diabetes, Obesity & Metabolism|February 18, 2014
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazoneT Forst, R Guthrie, R Goldenberg, et al.
Journal of the Autonomic Nervous System|October 7, 1996
Decreased sympatho-adrenal activity in diabetic patients with autonomic dysfunction following mental stressT Forst, A Pfützner, C Jahn, et al.
Diabetes, Obesity & Metabolism|May 9, 2009
Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function: results from the PioSwitch studyC Hohberg, A Pfützner, T Forst, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|August 18, 2006
Small neuroendocrine pancreatic tumors in multiple endocrine neoplasia type 1 (MEN1): least significant change of tumor diameter as determined by endoscopic ultrasound (EUS) imagingP H Kann, B Kann, W J Fassbender, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|September 3, 2005
Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose controlA Pfützner, C Hohberg, G Lübben, et al.
Diabetes, Obesity & Metabolism|March 1, 2011
The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitusT Forst, B Uhlig-Laske, A Ring, et al.
Current Medical Research and Opinion|November 18, 2011
Self-assessment and objective determination of dexterity in patients with type 1 or type 2 diabetes mellitusAndreas Pfützner, P B Musholt, C Schipper, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|July 17, 2015
Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutideG Grunberger, T Forst, L Fernández Landó, et al.
Pageof 10

Showing results (41-50 of 96) with videos related to

Sort By:
Pageof 10
Clinical Laboratory|April 13, 2004
Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotypingA Weise, S Grundler, D Zaumsegel, et al.
Diabetes, Obesity & Metabolism|February 2, 2013
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metforminC Kapitza, T Forst, H-V Coester, et al.
Diabetes, Obesity & Metabolism|February 18, 2014
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazoneT Forst, R Guthrie, R Goldenberg, et al.
Journal of the Autonomic Nervous System|October 7, 1996
Decreased sympatho-adrenal activity in diabetic patients with autonomic dysfunction following mental stressT Forst, A Pfützner, C Jahn, et al.
Diabetes, Obesity & Metabolism|May 9, 2009
Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function: results from the PioSwitch studyC Hohberg, A Pfützner, T Forst, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|August 18, 2006
Small neuroendocrine pancreatic tumors in multiple endocrine neoplasia type 1 (MEN1): least significant change of tumor diameter as determined by endoscopic ultrasound (EUS) imagingP H Kann, B Kann, W J Fassbender, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|September 3, 2005
Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose controlA Pfützner, C Hohberg, G Lübben, et al.
Diabetes, Obesity & Metabolism|March 1, 2011
The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitusT Forst, B Uhlig-Laske, A Ring, et al.
Current Medical Research and Opinion|November 18, 2011
Self-assessment and objective determination of dexterity in patients with type 1 or type 2 diabetes mellitusAndreas Pfützner, P B Musholt, C Schipper, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|July 17, 2015
Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutideG Grunberger, T Forst, L Fernández Landó, et al.
Pageof 10